Scandinavian ChemoTech AB (publ) (CMOTEC-B.ST)
SEK 1.48
(0.68%)
SEK 1.48
(0.68%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -20.13 Million SEK | 3.7% |
| 2022 | -20.91 Million SEK | -22.46% |
| 2021 | -17.07 Million SEK | -57.7% |
| 2020 | -10.82 Million SEK | 9.54% |
| 2019 | -11.97 Million SEK | -148.52% |
| 2018 | -4.81 Million SEK | 41.82% |
| 2017 | -8.28 Million SEK | -2.73% |
| 2016 | -8.06 Million SEK | -601.46% |
| 2015 | -1.14 Million SEK | -3983.77% |
| 2014 | -28.13 Thousand SEK | -277.22% |
| 2013 | -7459.00 SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -3.74 Million SEK | -33.62% |
| 2024 Q1 | -2.79 Million SEK | 47.16% |
| 2023 Q2 | -5.97 Million SEK | -21.36% |
| 2023 Q4 | -5.29 Million SEK | -31.57% |
| 2023 FY | -20.13 Million SEK | 3.7% |
| 2023 Q1 | -4.92 Million SEK | 17.14% |
| 2023 Q3 | -4.02 Million SEK | 32.65% |
| 2022 Q2 | -5.74 Million SEK | -30.16% |
| 2022 FY | -20.91 Million SEK | -22.46% |
| 2022 Q4 | -5.94 Million SEK | -23.6% |
| 2022 Q3 | -4.81 Million SEK | 16.26% |
| 2022 Q1 | -4.41 Million SEK | 18.76% |
| 2021 FY | -17.07 Million SEK | -57.7% |
| 2021 Q1 | -2.62 Million SEK | 0.34% |
| 2021 Q2 | -3.77 Million SEK | -43.92% |
| 2021 Q3 | -5.24 Million SEK | -38.99% |
| 2021 Q4 | -5.43 Million SEK | -3.53% |
| 2020 Q2 | -2.41 Million SEK | 22.92% |
| 2020 FY | -10.82 Million SEK | 9.54% |
| 2020 Q3 | -2.65 Million SEK | -9.82% |
| 2020 Q1 | -3.13 Million SEK | 21.9% |
| 2020 Q4 | -2.63 Million SEK | 0.72% |
| 2019 FY | -11.97 Million SEK | -148.52% |
| 2019 Q2 | -2.2 Million SEK | 20.95% |
| 2019 Q4 | -4.01 Million SEK | -26.7% |
| 2019 Q1 | -2.79 Million SEK | -137.94% |
| 2019 Q3 | -3.16 Million SEK | -43.34% |
| 2018 Q3 | -836.26 Thousand SEK | 45.13% |
| 2018 FY | -4.81 Million SEK | 41.82% |
| 2018 Q4 | -1.17 Million SEK | -40.37% |
| 2018 Q2 | -1.52 Million SEK | -18.83% |
| 2018 Q1 | -1.28 Million SEK | 0.0% |
| 2017 Q1 | -2.43 Million SEK | -5.7% |
| 2017 FY | -8.28 Million SEK | -2.73% |
| 2017 Q3 | -2.31 Million SEK | 10.85% |
| 2017 Q2 | -2.6 Million SEK | -7.05% |
| 2016 Q1 | -244.61 Thousand SEK | 33.11% |
| 2016 FY | -8.06 Million SEK | -601.46% |
| 2016 Q4 | -2.29 Million SEK | -206.76% |
| 2016 Q2 | -442.16 Thousand SEK | -80.76% |
| 2016 Q3 | -749.72 Thousand SEK | -69.56% |
| 2015 Q4 | -365.7 Thousand SEK | -58.22% |
| 2015 Q3 | -231.13 Thousand SEK | 0.0% |
| 2015 FY | -1.14 Million SEK | -3983.77% |
| 2014 FY | -28.13 Thousand SEK | -277.22% |
| 2013 FY | -7459.00 SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -248.98 Million SEK | 91.911% |
| Ziccum AB (publ) | -21.56 Million SEK | 6.591% |
| Modus Therapeutics Holding AB (publ) | -16.4 Million SEK | -22.791% |
| BioArctic AB (publ) | 252.64 Million SEK | 107.971% |
| Sprint Bioscience AB (publ) | -845 Thousand SEK | -2283.314% |
| Mendus AB (publ) | -100.65 Million SEK | 79.991% |
| Genovis AB (publ.) | 54.22 Million SEK | 137.14% |
| Intervacc AB (publ) | -93.57 Million SEK | 78.479% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -15.51 Million SEK | -29.829% |
| Active Biotech AB (publ) | -46.48 Million SEK | 56.675% |
| Magle Chemoswed Holding AB (publ) | 18 Million SEK | 211.827% |
| Bio-Works Technologies AB (publ) | -55.41 Million SEK | 63.659% |
| Aptahem AB (publ) | -10.1 Million SEK | -99.302% |
| Vicore Pharma Holding AB (publ) | -321.5 Million SEK | 93.736% |
| Kancera AB (publ) | -65.04 Million SEK | 69.037% |
| Infant Bacterial Therapeutics AB (publ) | -134.61 Million SEK | 85.04% |
| Fluicell AB (publ) | -26.87 Million SEK | 25.075% |
| Saniona AB (publ) | -81.06 Million SEK | 75.157% |
| Lipigon Pharmaceuticals AB (publ) | -12.37 Million SEK | -62.792% |
| Biovica International AB (publ) | -126.07 Million SEK | 84.026% |
| Spago Nanomedical AB (publ) | -42.5 Million SEK | 52.62% |
| AcouSort AB (publ) | -17.48 Million SEK | -15.166% |
| Xintela AB (publ) | -57.23 Million SEK | 64.815% |
| Abliva AB (publ) | -96.54 Million SEK | 79.141% |
| Egetis Therapeutics AB (publ) | -324.8 Million SEK | 93.8% |
| Karolinska Development AB (publ) | -3.5 Million SEK | -474.579% |
| OncoZenge AB (publ) | -15.9 Million SEK | -26.644% |
| Amniotics AB (publ) | -29.07 Million SEK | 30.73% |
| 2cureX AB (publ) | -36.36 Million SEK | 44.617% |
| CombiGene AB (publ) | -36.3 Million SEK | 44.529% |
| Asarina Pharma AB (publ) | -14.64 Million SEK | -37.561% |
| Calliditas Therapeutics AB (publ) | -384.39 Million SEK | 94.761% |
| Camurus AB (publ) | 532.35 Million SEK | 103.783% |
| Corline Biomedical AB | -1.78 Million SEK | -1026.342% |
| IRLAB Therapeutics AB (publ) | -180.76 Million SEK | 88.859% |
| Isofol Medical AB (publ) | -41.68 Million SEK | 51.685% |
| I-Tech AB | 24.43 Million SEK | 182.419% |
| Hansa Biopharma AB (publ) | -788.49 Million SEK | 97.446% |
| Cyxone AB (publ) | -21.66 Million SEK | 7.026% |
| ExpreS2ion Biotech Holding AB (publ) | -105.96 Million SEK | 80.995% |
| Biosergen AB | -27.26 Million SEK | 26.136% |
| Cantargia AB (publ) | -290.01 Million SEK | 93.056% |
| NextCell Pharma AB | -43.17 Million SEK | 53.352% |
| Xspray Pharma AB (publ) | -180.76 Million SEK | 88.859% |
| Elicera Therapeutics AB (publ) | -17.09 Million SEK | -17.798% |
| Nanologica AB (publ) | -69.96 Million SEK | 71.215% |
| SynAct Pharma AB | -224.49 Million SEK | 91.029% |
| Annexin Pharmaceuticals AB (publ) | -44.17 Million SEK | 54.412% |
| Stayble Therapeutics AB (publ) | -23.95 Million SEK | 15.927% |
| LIDDS AB (publ) | -40.67 Million SEK | 50.487% |
| Lipum AB (publ) | -37.25 Million SEK | 45.941% |
| BioInvent International AB (publ) | -369.94 Million SEK | 94.556% |
| Alzinova AB (publ) | -16.52 Million SEK | -21.892% |
| Oncopeptides AB (publ) | -253.44 Million SEK | 92.054% |
| Pila Pharma AB (publ) | -6.39 Million SEK | -215.004% |
| Guard Therapeutics International AB (publ) | -115.07 Million SEK | 82.499% |
| Simris Alg AB (publ) | -36.63 Million SEK | 45.028% |
| Diamyd Medical AB (publ) | -146.56 Million SEK | 86.26% |
| Xbrane Biopharma AB (publ) | -310.42 Million SEK | 93.512% |
| Ascelia Pharma AB (publ) | -110.91 Million SEK | 81.843% |
| Diagonal Bio AB (publ) | -11.56 Million SEK | -74.122% |